Chordia Therapeutics Inc.

26-1, Muraoka-Higashi 2-chome, Fujisawa, Kanagawa 251-0012 Japan
info@chordiatherapeutics.com<Press Release>
May 19, 2022
Chordia Therapeutics Raises Approximately 4 billion JPY in Series C Financing,Achieving a Cumulative Total of Approximately 8.2 billion JPY
Kanagawa, Japan, May 19, 2022 – Chordia Therapeutics Inc. (“Chordia”), a biotech
company engaged in the research and development of novel therapies for cancers,
today announced that it has raised a total of approximately 4 billion JPY through athird-party allotment of new shares in the Series C round, with Japan Growth Capital
Investment Corporation and UTokyo Innovation Platform Co., Ltd. as lead investors,
underwritten by MEDIPAL Innovation Fund, Shinsei Capital Partners, Ltd., Nippon
Venture Capital Co., Ltd., and others.
Chordia will use the funds to advance clinical trials in Japan and abroad of CTX-712,
a selective pan-CDC-like kinase (“CLK”) inhibitor currently in Phase I, and accelerate
other pre-clinical programs of its other drug candidates.
Hiroshi Miyake, Ph.D., representative director of Chordia, said, “I am delighted that
this capital increase will enable us to accelerate the development of our clinical andpre-clinical assets in our pipeline. CTX-712 targets the vulnerability resulting fromRNA deregulation, which has been identified as a novel hallmark of cancer, and isexpected to be an effective therapeutic agent because it has a new mechanism of actionthat is completely different from conventional anticancer drugs. We are committed tomaking daily efforts to deliver epoch-making medicines to patients living with cancer
as soon as possible.”
In connection with the financing, Ichitaro Akita, Chief Investment Officer of Nomura
SPARX Investment, Inc., which is the asset management company of Japan Growth
Capital Investment Corporation, and Makoto (Mark) Ohori, Ph.D., Partner and ChiefInvestment Officer, Life Science at UTokyo IPC have joined Chordia’s board ofdirectors.
Ichitaro Akita said, “There is not radical treatment for many cancers, and it is thoughtthat unmet medical needs for the anticancer drugs are high. Through the efficient
allocation of capital by Chordia, NSPI looks forward to Chordia’s growth in thedevelopment of drugs for the treatment of cancers with unmet medical needs.”“RNA deregulation as a novel hallmark of cancer is an exciting area where we makedrug discovery efforts,” said Mark Ohori. “We are proud to support the company as it
works to fulfill the promise of CTX-712 for treatment of malignant cancers anddevelops further pipelines that leverage its expertise in the RNA deregulation field.”
About Chordia Therapeutics
Chordia was established in November 2017 at Shonan Health Innovation Park(“Shonan iPark”) in Fujisawa, Kanagawa Prefecture, as a biotech company engaged

Chordia Therapeutics Inc.

26-1, Muraoka-Higashi 2-chome, Fujisawa, Kanagawa 251-0012 Japan
info@chordiatherapeutics.com

in the research and development of novel therapies for cancers, with the goal ofresearching and developing first-in-class anti-cancer drugs and creating innovative
new drugs.
In addition to its leading program for CTX-712, Chordia is engaged in the research of
several developments in our pipeline, including CTX-439, a CDK12 inhibitor, whichis expected to be effective in cancers with specific abnormalities, as well as GCN2inhibitors.
Established:
Address:Representative:
Website:November 2017
26-1, Muraoka-Higashi 2-chome, Fujisawa,
Kanagawa 251-0012, Japan
Hiroshi Miyake, Representative Director
https://www.chordiatherapeutics.com/en/

For more information, contact Kentaro Kume, IR: info@chordiatherapeutics.com